Kymera Therapeutics, Inc. (KYMR) News
Follow Kymera Therapeutics, Inc. (KYMR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 28 public stories across 19 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Kymera Therapeutics price target raised to $152 by Stifel
Stifel raised its price target on Kymera Therapeutics to $152 from $132, maintaining a Buy rating.
EQUITY | Sep 22, 2026, 10:54 AM UTC
L
KYMR: KT-621's clinical progress positions it to transform oral therapy options in atopic dermatitis
The session highlighted advances in targeted protein degradation, with a focus on immunology and key programs like KT-621 (STAT6 degrader) and KT-579 (IRF5 degrader). KT-621 shows strong clinical promise for atopic derma
NEWS | Sep 15, 2026, 01:38 PM UTC
L
KYMR: KT-621's rapid clinical progress and broad potential highlight a major shift in immunology treatment
The company is advancing oral targeted protein degraders in immunology, with KT-621 showing strong early clinical results and high market potential in atopic dermatitis. Rapid enrollment and robust trial design support c
NEWS | Sep 15, 2026, 12:51 PM UTC
L
KYMR: STAT6 program advances with phase IIb data expected by year-end, supporting phase III plans
The conference highlighted advances in targeted protein degradation, with lead programs STAT6 and IRF5 progressing through clinical stages. STAT6 showed strong efficacy and safety in atopic dermatitis, with phase IIb dat
NEWS | Sep 14, 2026, 09:52 PM UTC
L
KYMR: STAT6 and IRF5 programs advance in immunology, with pivotal phase II data expected by year-end
The conference highlighted advances in targeted protein degradation, with robust clinical progress for STAT6 and IRF5 programs addressing major immunology markets. Key phase II data for atopic dermatitis and asthma are e
NEWS | Sep 14, 2026, 09:51 PM UTC
L
KYMR: STAT6 and IRF5 advance in clinic, with pivotal phase IIb data for STAT6 due by year-end
The conference highlighted advances in targeted protein degradation, with lead programs STAT6 and IRF5 progressing through clinical stages. STAT6 showed strong efficacy and safety in atopic dermatitis, with phase IIb dat
NEWS | Sep 14, 2026, 09:10 PM UTC
L
Kymera Therapeutics raised to Outperform by Wolfe Research
EQUITY | Sep 10, 2026, 01:46 PM UTC
L
KYMR: Accelerated STAT6 program advances toward Phase III, targeting first-in-class oral therapies
Revised summary: The conference highlighted rapid STAT6 program progress, with accelerated enrollment and strong early data supporting Phase III for atopic dermatitis and asthma. Focus areas include pediatric expansion,
EQUITY | Sep 09, 2026, 01:57 PM UTC
L
KYMR says it accelerated STAT6 trial enrollment and outlined expansion plans
KYMR highlighted accelerated enrollment in pivotal STAT6 trials for atopic dermatitis and asthma, citing a strong safety profile. It also plans aggressive expansion across indications, with a focus on pediatric populatio
EQUITY | Sep 09, 2026, 01:28 PM UTC
L
Kymera legal chief sold shares worth more than $744K
Brian Adams, Chief Legal Officer at Kymera Therapeutics, sold shares of common stock on September 4, 2026, to cover tax withholding tied to restricted stock unit vesting. Shares sold were worth over $744K.
EQUITY | Sep 04, 2026, 10:10 PM UTC
L
KYMR - Kymera Therapeutics to Participate in Upcoming September Investor Conferences
KYMR - Kymera Therapeutics to Participate in Upcoming September Investor Conferences
EQUITY | Sep 02, 2026, 08:01 PM UTC
L
Kymera Therapeutics to present KT-621 at European medical congresses
Kymera Therapeutics announced presentations on KT-621, an oral first-in-class STAT6 degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology congresses.
EQUITY | Sep 01, 2026, 11:01 AM UTC
L
Wells Fargo raises Kymera Therapeutics price target to $151
Wells Fargo raised its Kymera Therapeutics price target to $151.00 per share from $116.00.
EQUITY | Aug 27, 2026, 01:54 PM UTC
L
KYMR - Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
KYMR - Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
EARNINGS | Aug 05, 2026, 11:00 AM UTC
L
KYMR Initiated Hold W/$120.00 PT at Deutsche Bank
KYMR Initiated Hold W/$120.00 PT at Deutsche Bank
EQUITY | Jul 30, 2026, 12:01 PM UTC
H
KYMR Rated Hold
KYMR rated hold with $120 price target
EQUITY | Jul 30, 2026, 11:29 AM UTC
H
Deutsche Bank rates Kymera HOLD
Deutsche Bank initiates Kymera at HOLD
EQUITY | Jul 30, 2026, 10:42 AM UTC
L
KYMR Think Co should be credited value if KT-579 shows healthy volunteer data in 2H26 that demonstrates safe >90% IRF5 degradation @ GUGG
KYMR Think Co should be credited value if KT-579 shows healthy volunteer data in 2H26 that demonstrates safe >90% IRF5 degradation @ GUGG
EQUITY | Jul 28, 2026, 01:27 PM UTC
L
KYMR Maintain Overweight and $140 PT ahead of two key readouts expected later this year @ Piper
KYMR Maintain Overweight and $140 PT ahead of two key readouts expected later this year @ Piper
EQUITY | Jul 16, 2026, 12:25 PM UTC
L
American Express, Biogen upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: JPMorgan upgraded American Express
EQUITY | Jul 13, 2026, 01:43 PM UTC
L
Kymera Therapeutics Insider Sold Shares Worth $5,950,000, According to a Recent SEC Filing
() -- Nello Mainolfi, Director, Chief Executive Officer, on July 07, 2026, sold 50,000 shares in Kymera Therapeutics (KYMR) for $5,950,000. Following the Form 4 filing with the SEC, Mainolfi has control over a total of 6
REGULATION | Jul 08, 2026, 07:32 AM UTC
L
Kymera Therapeutics shares are trading higher after B of A Securities raised its price target on the stock from $110 to $125.
Kymera Therapeutics shares are trading higher after B of A Securities raised its price target on the stock from $110 to $125.
EQUITY | Jun 30, 2026, 05:08 PM UTC
L
B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $125
B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ: KYMR ) with a Buy and raises the price target from $110 to $125.
EQUITY | Jun 30, 2026, 02:56 PM UTC
M
B. Riley Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $155
B. Riley Securities analyst Kalpit Patel maintains Kymera Therapeutics (NASDAQ: KYMR ) with a Buy and raises the price target from $117 to $155.
EQUITY | Jun 29, 2026, 02:35 PM UTC
M
KYMR: Canaccord Genuity Raises PT
Canaccord Genuity analyst Edward Nash maintains Kymera Therapeutics with a Buy and raises the price target from $106 to $129
EQUITY | Jun 26, 2026, 03:07 PM UTC
M
Kymera Completes Enrollment
Kymera Therapeutics completes enrollment in global BROADEN2 Phase 2b trial of KT-621 for atopic dermatitis treatment
EQUITY | Jun 25, 2026, 11:04 AM UTC
M
KYMR Completes Enrollment
Kymera Therapeutics completes enrollment in the Phase 2b BROADEN2 trial of KT-621 in atopic dermatitis with topline data expected by year-end 2026
EQUITY | Jun 25, 2026, 11:00 AM UTC